gastric cancer

2 curated biomarkers

← Back to browse

FDA-approved treatments

ERBB2
- Perjeta (pertuzumab) [ema]
- Herceptin (trastuzumab) [fda]
- Enhertu (trastuzumab deruxtecan) [fda]
- Tukysa (tucatinib) [fda]
PD-L1
- Tecentriq (atezolizumab) [fda]
- Imfinzi (durvalumab) [fda]
- Opdivo (nivolumab) [fda]
- Keytruda (pembrolizumab) [ema]

Prevalence

ERBB2
HER2 is overexpressed or amplified in approximately 15%-20% of breast cancers and approximately 15%-20% of gastric/gastroesophageal junction adenocarcinomas.[fda]
PD-L1
PD-L1 expression thresholds and prevalence vary substantially by tumor type and assay; high PD-L1 expression (TPS >= 50%) is seen in approximately 25%-30% of NSCLC by validated companion diagnostic assays.[fda]

Tests / detection method

ERBB2
IHC, ISH/FISH, NGS (amplification calling)
PD-L1
IHC

Therapeutic pipeline

ERBB2
- Bispecific HER2-targeted antibodies [fda]
- Next-generation HER2-directed antibody-drug conjugates (HER2-ultralow expression) [fda]
PD-L1
- Next-generation immune checkpoint combinations (e.g., LAG-3, TIGIT co-blockade) (LAG-3 expression, TIGIT expression) [fda]

PubMed Central · Oct 1, 2026
Impact of Non-curative Endoscopic Submucosal Dissection on Minimally Invasive Distal Gastrectomy and on Robotic Versus Laparoscopic Approaches in pT1 Gastric Cancer.
Read at PubMed Central
PubMed Central · Oct 1, 2026
Integrated Single-Cell and Spatial Transcriptomics Reveal SERPINE1 as a Key Link Between Macro_SPP1 Macrophages and Stromal Remodeling in Gastric Cancer.
Read at PubMed Central
PubMed Central · Oct 1, 2026
Hereditary Diffuse Gastric Cancer With Poorly Differentiated Gallbladder Adenocarcinoma: A Case Report Suggesting Carcinogenesis in the Stomach and Gallbladder Caused by a Pathogenic Germline Variant in CDH1.
Read at PubMed Central
PubMed Central · Sep 3, 2026
Barriers and Priorities for Immunotherapy Implementation in Advanced Gastric Cancer: Findings from a Two-Phase Qualitative Study.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Preoperative RDW-Albumin Ratio as a Prognostic Biomarker in Gastric Cancer Surgery.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Tumor-Associated Macrophages in the Chemoresistant Microenvironment of Gastric Cancer: Key Mechanisms and Intercellular Crosstalk.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Integrative Multi-Omics Analysis Identifies Thrombosis-Associated Molecular Features Linked to Germline Susceptibility and Immune Cell Communication in Gastric Cancer.
Read at PubMed Central
PubMed Central · Aug 31, 2026
Clinicopathological features, morbidity and survival in gastric adenocarcinoma, with a focus on stage III: a retrospective institutional cohort analysis.
Read at PubMed Central
PubMed Central · Aug 29, 2026
Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 28, 2026
The anticoagulation dilemma: A case report of pulmonary embolism in a gastric cancer patient with concurrent gastrointestinal bleeding and thrombocytopenia.
Read at PubMed Central
PubMed Central · Aug 26, 2026
Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 22, 2026
FMRP promotes gastric cancer progression via m(6)A-dependent stabilization of DVL2 and activation of the Wnt/PCP-JNK pathway.
Read at PubMed Central
PubMed Central · Aug 21, 2026
Global burden of esophagus cancer, stomach cancer and colon and rectal cancer from 1990 to 2050: A cross-sectional study.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 21, 2026
Role of mutant p53 and autophagy on precancerous lesions of gastric cancer progression: A review.
Read at PubMed Central
PubMed Central · Aug 21, 2026
Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer.
Read at PubMed Central
PubMed Central · Aug 21, 2026
Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review).
Read at PubMed Central
PubMed Central · Aug 20, 2026
Lipid metabolism and the immune microenvironment in gastric cancer.
Read at PubMed Central
PubMed Central · Aug 20, 2026
[Reflections on surgical management strategies for locally advanced gastric cancer after neoadjuvant immunotherapy].
Read at PubMed Central

gastric cancer

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for gastric cancer

Impact of Non-curative Endoscopic Submucosal Dissection on Minimally Invasive Distal Gastrectomy and on Robotic Versus Laparoscopic Approaches in pT1 Gastric Cancer.

Integrated Single-Cell and Spatial Transcriptomics Reveal SERPINE1 as a Key Link Between Macro_SPP1 Macrophages and Stromal Remodeling in Gastric Cancer.

Hereditary Diffuse Gastric Cancer With Poorly Differentiated Gallbladder Adenocarcinoma: A Case Report Suggesting Carcinogenesis in the Stomach and Gallbladder Caused by a Pathogenic Germline Variant in CDH1.

Barriers and Priorities for Immunotherapy Implementation in Advanced Gastric Cancer: Findings from a Two-Phase Qualitative Study.

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine.

Preoperative RDW-Albumin Ratio as a Prognostic Biomarker in Gastric Cancer Surgery.

Tumor-Associated Macrophages in the Chemoresistant Microenvironment of Gastric Cancer: Key Mechanisms and Intercellular Crosstalk.

Integrative Multi-Omics Analysis Identifies Thrombosis-Associated Molecular Features Linked to Germline Susceptibility and Immune Cell Communication in Gastric Cancer.

Clinicopathological features, morbidity and survival in gastric adenocarcinoma, with a focus on stage III: a retrospective institutional cohort analysis.

Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.

The anticoagulation dilemma: A case report of pulmonary embolism in a gastric cancer patient with concurrent gastrointestinal bleeding and thrombocytopenia.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

FMRP promotes gastric cancer progression via m(6)A-dependent stabilization of DVL2 and activation of the Wnt/PCP-JNK pathway.

Global burden of esophagus cancer, stomach cancer and colon and rectal cancer from 1990 to 2050: A cross-sectional study.

Role of mutant p53 and autophagy on precancerous lesions of gastric cancer progression: A review.

Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer.

Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review).

Lipid metabolism and the immune microenvironment in gastric cancer.

[Reflections on surgical management strategies for locally advanced gastric cancer after neoadjuvant immunotherapy].